Abstract
The aim of this review is to summarize present knowledge of genetic variation in cytochrome P450 1B1 (CYP1B1) and 2C9 (CYP2C9) genes and risk of tobacco-related cancer, female cancer, chronic obstructive pulmonary disease and ischemic vascular disease. The CYP1B1 and CYP2C9 enzymes metabolize polycyclic aromatic hydrocarbons found in tobacco smoke and thereby generate disease-causing metabolites suggested to be important in tobacco-related diseases. Furthermore, CYP1B1 also metabolizes estrogen while CYP2C9 metabolizes arachidonic acid, both creating metabolites potentially important in risk of female cancer or ischemic vascular disease. Genetic variation in genes coding for CYP1B1 and CYP2C9 enzymes have shown altered enzyme activity affecting levels of metabolites and thus potentially risk of disease. So far, however, findings have been inconsistent. Recently, large studies on the association between genetic variation in CYP1B1 and CYP2C9 and risk of disease with considerable statistical power rebutted the hypotheses that these genetic variants affect risk of tobacco-related cancer, female cancer, chronic obstructive pulmonary disease and ischemic vascular disease.
Keywords: Arachidonic acid, CYP1B1, CYP2C9, general population, polycyclic aromatic hydrocarbons, single nucleotide polymorphism, tobacco, 17β-estradiol, chronic obstructive pulmonary disease, ischemic vascular disease
Current Vascular Pharmacology
Title:Cytochrome P450 1B1 and 2C9 Genotypes and Risk of Ischemic Vascular Disease, Cancer, and Chronic Obstructive Pulmonary Disease
Volume: 10 Issue: 4
Author(s): Diljit Kaur-Knudsen, Stig E. Bojesen and Borge G. Nordestgaard
Affiliation:
Keywords: Arachidonic acid, CYP1B1, CYP2C9, general population, polycyclic aromatic hydrocarbons, single nucleotide polymorphism, tobacco, 17β-estradiol, chronic obstructive pulmonary disease, ischemic vascular disease
Abstract: The aim of this review is to summarize present knowledge of genetic variation in cytochrome P450 1B1 (CYP1B1) and 2C9 (CYP2C9) genes and risk of tobacco-related cancer, female cancer, chronic obstructive pulmonary disease and ischemic vascular disease. The CYP1B1 and CYP2C9 enzymes metabolize polycyclic aromatic hydrocarbons found in tobacco smoke and thereby generate disease-causing metabolites suggested to be important in tobacco-related diseases. Furthermore, CYP1B1 also metabolizes estrogen while CYP2C9 metabolizes arachidonic acid, both creating metabolites potentially important in risk of female cancer or ischemic vascular disease. Genetic variation in genes coding for CYP1B1 and CYP2C9 enzymes have shown altered enzyme activity affecting levels of metabolites and thus potentially risk of disease. So far, however, findings have been inconsistent. Recently, large studies on the association between genetic variation in CYP1B1 and CYP2C9 and risk of disease with considerable statistical power rebutted the hypotheses that these genetic variants affect risk of tobacco-related cancer, female cancer, chronic obstructive pulmonary disease and ischemic vascular disease.
Export Options
About this article
Cite this article as:
Kaur-Knudsen Diljit, E. Bojesen Stig and G. Nordestgaard Borge, Cytochrome P450 1B1 and 2C9 Genotypes and Risk of Ischemic Vascular Disease, Cancer, and Chronic Obstructive Pulmonary Disease, Current Vascular Pharmacology 2012; 10 (4) . https://dx.doi.org/10.2174/157016112800812746
DOI https://dx.doi.org/10.2174/157016112800812746 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of Sulfated Fucans as Anticoagulant and Antithrombotic Agents: Future Perspectives
Current Pharmaceutical Design Experimental and Theoretical Study on the Electrochemical Behavior of Zofenopril and its Voltammetric Determination
Current Pharmaceutical Analysis Fluorescent Probes for Cellular Assays
Combinatorial Chemistry & High Throughput Screening Levosimendan for Perioperative Cardioprotection: Myth or Reality?
Current Cardiology Reviews Immunomodulatory Effects of Agarwood Leaf Extract on RAW264.7 Murine Macrophages
Endocrine, Metabolic & Immune Disorders - Drug Targets Aldosterone to Renin Ratio (ARR) in Clinical use, with Reference to the Primary Care Setting: ARR to Whom, When, How, What for?
Current Hypertension Reviews Are Cerebral Perfusion and Atrophy Linked in Multiple Sclerosis? Evidence for a Multifactorial Approach to Assess Neurodegeneration
Current Neurovascular Research Aspirin as a Chemoprevention Agent for Colorectal Cancer
Current Drug Metabolism Tako-tsubo Cardiomyopathy: A Review of the Literature
Current Cardiology Reviews Beyond Cholesterol Lowering: Pleiotropic Effects of Bile Acid Binding Resins Against Cardiovascular Disease Risk Factors in Patients with Metabolic Syndrome
Current Vascular Pharmacology Patented Biomarkers of Peripheral Blood for the Early Detection of Cancer
Recent Patents on Biomarkers An Angiotensin II (Ang II) Type 1 Receptor Blocker, Telmisartan Protects Against Neurological Deficits and Prolongs Survival in Spontaneously Hypertensive Rats Stroke-Prone (SHR-SP) Infused with Ang II
Vascular Disease Prevention (Discontinued) Target Fishing of Calactin, Calotropin and Calotoxin Using Reverse Pharmacophore Screening and Consensus Inverse Docking Approach
Current Drug Discovery Technologies Use of Cell Lines in the Investigation of Pharmacogenetic Loci
Current Pharmaceutical Design Connexin Modulators and Their Potential Targets under the Magnifying Glass
Current Medicinal Chemistry Relevance of Endothelial-Haemostatic Dysfunction in Cigarette Smoking
Current Medicinal Chemistry Angiotensin Receptor Blockers in Hypertension and Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry The Endocannabinoid Signaling System: A Potential Target for Next- Generation Therapeutics for Alcoholism
Mini-Reviews in Medicinal Chemistry Chitosan Nanoparticles: An Approbative System for the Delivery of Herbal Bioactives
The Natural Products Journal Anti-Cancer / Anti-Tumor
Current Bioactive Compounds